OS Therapies Incorporated (OSTX)

Market Cap	52.82M
Revenue (ttm)	n/a
Net Income (ttm)	-20.26M
Shares Out	35.21M
EPS (ttm)	-0.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	423,882
Open	1.530
Previous Close	1.500
Day's Range	1.480 - 1.538
52-Week Range	1.120 - 3.530
Beta	n/a
Analysts	Strong Buy
Price Target	18.50 (+1,133.33%)
Earnings Date	Nov 17, 2025

About OSTX

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 1, 2024
• Employees: 5
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: OSTX
• Website: https://ostherapies.com

Analyst Summary

According to 2 analysts, the average rating for OSTX stock is "Strong Buy." The 12-month stock price target is $18.5, which is an increase of 1,133.33% from the latest price.

Price Target

$18.5

(1,133.33% upside)

Analyst Consensus: Strong Buy